Jpmorgan Chase & CO Rallybio Corp Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Rallybio Corp stock. As of the latest transaction made, Jpmorgan Chase & CO holds 882 shares of RLYB stock, worth $873. This represents 0.0% of its overall portfolio holdings.

Number of Shares

882

Previous 882 -0.0%

Holding current value

$873

Previous $1,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.34 - $2.98 $18,371 - $40,855	-13,710 Reduced 93.96%	882 $1,000
Q1 2024 May 10, 2024	SELL	$1.25 - $2.4 $6,725 - $12,912	-5,380 Reduced 26.94%	14,592 $26,000
Q4 2023 Feb 12, 2024	SELL	$1.91 - $4.39 $3 - $8	-2 Reduced 0.01%	19,972 $47,000
Q3 2023 Nov 14, 2023	SELL	$3.37 - $6.16 $15,869 - $29,007	-4,709 Reduced 19.08%	19,974 $67,000
Q2 2023 Aug 11, 2023	SELL	$4.31 - $8.89 $28,764 - $59,331	-6,674 Reduced 21.28%	24,683 $139,000
Q1 2023 May 18, 2023	BUY	$4.37 - $8.75 $62,984 - $126,113	14,413 Added 85.06%	31,357 $179,000
Q1 2023 May 11, 2023	BUY	$4.37 - $8.75 $24,402 - $48,860	5,584 Added 49.15%	16,944 $96,000
Q4 2022 Feb 13, 2023	BUY	$4.67 - $14.86 $2,629 - $8,366	563 Added 5.21%	11,360 $74,000
Q3 2022 Nov 14, 2022	BUY	$7.54 - $14.56 $5,941 - $11,473	788 Added 7.87%	10,797 $156,000
Q2 2022 Aug 11, 2022	SELL	$6.26 - $13.65 $14,804 - $32,282	-2,365 Reduced 19.11%	10,009 $75,000
Q1 2022 May 11, 2022	SELL	$6.91 - $15.04 $2.18 Million - $4.75 Million	-315,840 Reduced 96.23%	12,374 $86,000
Q4 2021 Feb 10, 2022	BUY	$9.3 - $19.91 $2.54 Million - $5.44 Million	273,209 Added 496.7%	328,214 $3.13 Million
Q3 2021 Nov 12, 2021	BUY	$10.83 - $23.4 $595,704 - $1.29 Million	55,005 New	55,005 $967,000

Others Institutions Holding RLYB

# of Institutions

Shares Held

31.9M

Call Options Held

Put Options Held

View Full List

About Rallybio Corp

Ticker RLYB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,132,000
Market Cap $31.8M
Description
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...

More about RLYB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Rallybio Corp Transaction History